A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

To be part of this study, you need to be an adult (18 years or older) with a confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). You might be eligible if you're newly diagnosed or if you've tried exactly one other specific type of CML medication before. Importantly, your doctor must have already decided that asciminib or one of the other study medications is the right treatment for you as part of your usual care.

There are also some reasons why you might not be able to join. For instance, if you have certain genetic changes in your cancer that affect how well asciminib works, or if you're already taking CML medicine in a way that's not officially approved. You also can't be in another medical study at the same time. You'll need to be able to understand and sign a consent form.

If you decide to take part in this study, you won't be getting a new, untested treatment. Instead, you'll be receiving asciminib or another CML medication (like imatinib, dasatinib, bosutinib, or nilotinib) as your doctor has already decided for your regular care. The study largely involves collecting information from your routine follow-up visits with your doctor. This means you'll continue with your usual appointments, and the doctors will simply be noting details about how your treatment is going.

You might also be asked to complete some questionnaires yourself during the study. These questionnaires help understand how you're feeling and how the treatment is affecting your daily life. The doctors will follow your progress over time, but the exact duration of your participation isn't specified, as it generally follows your ongoing treatment plan. The study fits in with your normal medical care, rather than adding extra appointments specifically for research.